A. Arahmani

发表

Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

S. Loi, S. Loibl, F. André, 2019, Clinical Cancer Research.

OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).

R. Gelber, A. Tutt, J. Garber, 2015 .

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer.

M. Piccart, S. Lakhani, K. Gelmon, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

R. Gelber, M. Piccart, S. Lakhani, 2021, The New England journal of medicine.

Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer

R. Gelber, M. Piccart, J. Baselga, 2021, British Journal of Cancer.

OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.

R. Gelber, A. Tutt, S. Lakhani, 2021 .

Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer

Marion Procter, Thomas Suter, R. Gelber, 2017, The New England journal of medicine.

216TiPOlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)

R. Gelber, A. Tutt, J. Garber, 2017 .

DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer.

M. Piccart, T. Goulioti, G. Zoppoli, 2023, Future Oncology.

Patient (pt)-reported function and symptoms in APHINITY: A randomized comparison of chemotherapy (C) + trastuzumab (H) + placebo (Pla) versus C + H + pertuzumab (P) as adjuvant therapy in pts with HER2-positive early breast cancer (EBC).

R. Gelber, J. Baselga, G. Viale, 2018 .

Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

R. Gelber, M. Piccart, J. Baselga, 2019, Clinical breast cancer.